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Prevalence of respiratory distress syndrome (RDS) caused by primary surfactant deficiency reaches 50% in infants 
below 32 weeks of gestational age. Increased alveolar surface tension leads to atelectatic and/or dystelectatic lung 
areas followed by inflammation resulting in development of a bronchopulmonary dysplasia (BPD) in 8% of these 
children. Standard RDS treatment consists of administration of exogenous surfactant. With the introduction of less 
invasive application (LISA) of exogenous surfactant, the use of Surfactant has significantly increased. Pituitary 
adenylate cyclase-activating polypeptide (PACAP) and its receptors (VPAC1, VPAC2, PAC1) trigger 
inflammatory reactions as well as anti-inflammatory processes. 
Materials and methods 
Using cell cultures, FACS and ELISA methods we analyzed surfactant effects on inflammation and 
PACAP-regulation and of its receptors in vivo and ex vivo. 
Results 
We were able to show that lipopolysaccharide (LPS) in prestimulated cells (PBMC) after surfactant treatment 
resulted in a significant up-regulation of pro-inflammatory interleukin (IL)-8. In tracheal secretory cells of 
surfactant-treated neonates we found an up-regulation of pro-inflammatory receptor VPAC1. Furthermore, in cell 
cultures we identified changes in the proliferation rates. Amniotic infection syndrome (AIS) is one of the major 
causes for premature birth resulting in RDS requiring exogenous surfactant. After pre-stimulation of PBMCs and 
subsequent addition of surfactant, pro-inflammatory signals were fortified. These results were confirmed by 
analysis of tracheal secretions of preterms and newborns. 
Conclusions 
Current findings may imply that safety and efficacy of routine surfactant administration should be reassessed as 
surfactant potentially triggers pulmonary inflammation and thus may contribute to BPD development. 
